Lisanti Capital Growth, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 5, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$372.9M2026 Q3
Positions95
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.22.4%
What Changed This Quarter?
Top Holdings
CORT
Corcept Therapeutics
2.8%
HNGE
Hinge Health
2.7%
KNSA
Kiniksa Pharmaceuticals
2.6%
MGNI
Magnite
2.4%
CDNA
CareDx
2.3%
HTFL
Heartflow
2.1%
ZETA
Zeta Global
2.1%
GKOS
Glaukos
1.9%
New / Increased
52 new · 13 increased
CDNANEW
Caredx
2.3%
GKOSNEW
Glaukos
1.9%
ELFNEW
E L F
1.7%
BMRNNEW
Biomarin Pharmaceutical
1.7%
TWSTNEW
Twist Bioscience
1.5%
PI
Impinj
1.5%
+462.0%
DGII
Digi
1.4%
+208.3%
KNSA
Kiniksa Pharmaceuticals
2.6%
+48.0%
Reduced / Exited
29 reduced · 66 sold out
LIND
Lindblad Expeditions Hldgs
0.4%
-73.3%
XMTR
Xometry
1.7%
-39.6%
HNGE
Hinge Health
2.7%
-26.9%
ZETA
Zeta Global
2.1%
-30.4%
SEI
Solaris Energy Infras
1.3%
-40.7%
BTSGEXIT
Brightspring Health Services
2.4%
ALGMEXIT
Allegro Microsystems
1.7%
MIRMEXIT
Mirum Pharmaceuticals
1.6%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.